GH Research PLC

GHRS · NASDAQ · Healthcare / Biotechnology

19.10USD+0.61 (+3.30%)

Price History

Full chart

Market Stats

Previous Close18.49

Open18.84

Day Range18.00 – 19.81

52-Week Range12.04 – 31.44

Volume560.06K

Market Cap1.68B

P/E (TTM)0.00

Forward P/E0.00

EPS-0.93

Dividend Yield0.00%

Beta1.28

50-Day Avg28.35

200-Day Avg20.62

About

GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

Company Details

SectorHealthcare
IndustryBiotechnology
CEODr. Velichka Valcheva M.D., M.Sc.
Employees73
HeadquartersJoshua Dawson House, Dublin, Ireland, D02 RY95, USA
Websitehttps://www.ghres.com

Leadership

Mr. Florian Schonharting M.Sc. (Econ)Co-Founder & Non-Executive Chairman of the Board · b. 1969
Dr. Velichka Valcheva M.D., M.Sc.Chief Executive Officer · b. 1975
Mr. Magnus HalleCo-Founder & MD of Ireland · b. 1997
Ms. Julie Ryan F.C.A.Vice President of Finance · b. 1986
Mr. Aaron Cameron M.B.A.Chief Operating Officer · b. 1985

Financials

Income Statement

Currency: USD	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	0	0	0	0	0	0	0
Cost of Revenue	-	-	19.00K	47.00K	315.00K	315.00K	335.00K
Gross Profit	-	-	-19.00K	-47.00K	-315.00K	-315.00K	-335.00K
Operating Expense	-	-	15.08M	30.51M	40.91M	50.00M	60.34M
Operating Income	-310.00K	-446.00K	-15.10M	-30.55M	-41.22M	-50.31M	-60.68M
EBITDA	-310.00K	-445.00K	-9.17M	-22.41M	-35.21M	-38.60M	-47.46M
Net Income	-310.00K	-446.00K	-9.20M	-22.46M	-35.59M	-38.96M	-48.26M
R&D	296.00K	338.00K	8.55M	20.48M	29.82M	35.02M	38.73M
Interest Expense	0	0	9.00K	8.10M	723.00K	717.00K	463.00K

Balance Sheet

Currency: USD	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	504.00K	5.91M	279.92M	254.36M	226.30M	188.27M	288.23M
Total Liabilities	104.00K	246.00K	2.75M	4.55M	7.33M	9.32M	8.53M
Total Equity	400.00K	5.67M	277.18M	249.82M	218.97M	178.95M	279.70M
Cash	498.00K	5.89M	276.78M	165.96M	78.42M	100.79M	246.25M
Total Debt	-	-	-	-	974.00K	624.00K	512.00K
Net Debt	-498.00K	-5.89M	-276.78M	-165.96M	-77.45M	-100.17M	-245.74M

Cash Flow

Currency: USD	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-289.00K	-330.00K	-15.28M	-26.20M	-33.34M	-42.28M	-43.55M
Investing Cash Flow	-104.00K	-21.00K	-104.00K	-84.69M	-54.10M	65.14M	46.17M
Financing Cash Flow	797.00K	5.50M	286.45M	0	-204.00K	-304.00K	139.65M
Capital Expenditure	104.00K	21.00K	104.00K	67.00K	100.00K	49.00K	121.00K
Free Cash Flow	-289.00K	-330.00K	-15.39M	-26.27M	-33.44M	-42.33M	-43.67M
FCF to OCF	100.00%	100.00%	100.68%	100.26%	100.30%	100.12%	100.28%

Earnings

Report Date	Mar 31, 2020	Mar 31, 2021	Jun 28, 2021	Sep 23, 2021	Dec 6, 2021	Mar 28, 2022	May 18, 2022	Aug 23, 2022	Nov 10, 2022	Mar 2, 2023	May 11, 2023	Aug 23, 2023	Nov 9, 2023	Feb 29, 2024	May 3, 2024	Sep 3, 2024	Nov 14, 2024	Feb 27, 2025	May 8, 2025	Aug 7, 2025	Nov 6, 2025	Feb 26, 2026	May 14, 2026	Aug 6, 2026	Nov 5, 2026
EPS Estimate	0.00	0.00	0.00	-0.08	-0.17	-0.17	-0.16	-0.17	-0.16	-0.17	-0.19	-0.21	-0.20	-0.20	-0.22	-0.22	-0.25	-0.22	-0.20	-0.22	-0.23	-0.27	-0.26	-0.31	-0.27
EPS Actual	-0.00	-0.02	-0.01	-0.05	-0.04	-0.09	-0.11	0.01	-0.01	-0.32	-0.21	-0.15	-0.11	-0.21	-0.15	-0.20	-0.23	-0.17	-0.19	-0.15	-0.23	-0.22	-0.31	-0.23	-
Surprise	-	-	-	37.50%	76.47%	47.06%	31.25%	105.88%	93.75%	-88.24%	-10.53%	28.57%	45.00%	-5.00%	31.82%	9.09%	8.00%	23.32%	5.00%	31.82%	0.00%	17.85%	-19.23%	25.81%	-
Timing	-	-	After-hours	After-hours	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	After-hours	Pre-market	Pre-market	-	Pre-market	-	Pre-market	Pre-market	Pre-market	-	Pre-market	Pre-market	Pre-market

Key Statistics & Ratios

Market Cap1.68B

Enterprise Value1.42B

Trailing P/E0.00

Forward P/E0.00

Price / Sales0.00

Price / Book4.96

EPS-0.93

Book Value5.24

Revenue (TTM)0

Gross Profit (TTM)0

EBITDA-71.33M

Profit Margin0.00%

Operating Margin0.00%

Return on Equity-18.79%

Return on Assets-13.02%

Shares Outstanding68.64M

Shares Float32.37M

Beta1.28

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Analyst Ratings

Strong Buy

Based on 8 analystsTarget 42.89

Strong Buy
5
Buy
3

Ownership Breakdown

Institutions: 71.40%
Insiders: 24.44%
Retail / Other: 4.16%

Top Institutional Holders

Bvf Inc
8.65M12.60%
RA Capital Management, LLC
7.68M11.18%
RTW INVESTMENTS, LLC
5.93M8.64%
FMR Inc
5.14M7.48%
Deep Track Capital, LP
3.33M4.86%
venBio Select Advisor LLC
1.80M2.62%
The Toronto-Dominion Bank
1.40M2.04%
Foresite Capital Management VI LLC
940.49K1.37%
Jefferies Financial Group Inc
712.30K1.04%
BlackRock Inc
455.62K0.66%
UBS Group AG
412.42K0.60%
Millennium Management LLC
323.40K0.47%
BOOTHBAY FUND MANAGEMENT, LLC
282.89K0.41%
HighVista Strategies LLC
158.77K0.23%
Marshall Wace Asset Management Ltd
91.11K0.13%

Top Fund Holders

Fidelity Growth Company Fund
1.90M2.76%
Fidelity Growth Company K6
616.54K0.90%
Fidelity Series Growth Company
476.70K0.69%
iShares Biotechnology ETF
365.44K0.53%
Fidelity Select Biotechnology
173.40K0.25%